3201 Carnegie Avenue
United States - Map
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. The companys lead platform product, MultiStem cell therapy, an allogeneic stem cell product, which has Phase I clinical trials for the patients that have suffered an acute myocardial infarction, and leukemia or other blood-borne cancers; and is ongoing Phase II clinical trials for the patients suffering from inflammatory bowel disease (IBD) and ischemic stroke. Its clinical development programs are focused on treating inflammatory and immune disorders, neurological conditions, cardiovascular disease, and other conditions. The company is also involved in identifying and developing small pharmaceuticals to treat obesity; related metabolic conditions, such as diabetes; and neurological indications, including schizophrenia. It has collaboration agreement with Pfizer Inc. to develop and commercialize MultiStem to treat IBD; and RTI Biologics, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market. The company was founded in 1995 and is headquartered in Cleveland, Ohio.
|Dr. Gil Van Bokkelen Ph.D.,
Co-Founder, Chairman and Chief Exec. Officer
|Mr. William Lehmann Jr., J.D., MBA,
Pres, Chief Operating Officer and Sec.
|Dr. John J. Harrington Ph.D.,
Co-Founder, Chief Scientific Officer, Exec. VP and Director
|Ms. Laura K. Campbell CPA,
Principal Financial Officer, Principal Accounting Officer and VP of Fin.
|Dr. Robert J. Deans Ph.D.,
Exec. VP of Regenerative Medicine
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|